Cargando…
A Prospective Pilot Trial for Pallidal Deep Brain Stimulation in Huntington’s Disease
BACKGROUND: Movement disorders in Huntington’s disease are often medically refractive. The aim of the trial was assessment of procedure safety of deep brain stimulation, equality of internal- and external-pallidal stimulation and efficacy followed-up for 6 months in a prospective pilot trial. METHOD...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4539552/ https://www.ncbi.nlm.nih.gov/pubmed/26347707 http://dx.doi.org/10.3389/fneur.2015.00177 |
_version_ | 1782386128154787840 |
---|---|
author | Wojtecki, Lars Groiss, Stefan J. Ferrea, Stefano Elben, Saskia Hartmann, Christian J. Dunnett, Stephen B. Rosser, Anne Saft, Carsten Südmeyer, Martin Ohmann, Christian Schnitzler, Alfons Vesper, Jan |
author_facet | Wojtecki, Lars Groiss, Stefan J. Ferrea, Stefano Elben, Saskia Hartmann, Christian J. Dunnett, Stephen B. Rosser, Anne Saft, Carsten Südmeyer, Martin Ohmann, Christian Schnitzler, Alfons Vesper, Jan |
author_sort | Wojtecki, Lars |
collection | PubMed |
description | BACKGROUND: Movement disorders in Huntington’s disease are often medically refractive. The aim of the trial was assessment of procedure safety of deep brain stimulation, equality of internal- and external-pallidal stimulation and efficacy followed-up for 6 months in a prospective pilot trial. METHODS: In a controlled double-blind phase six patients (four chorea-dominant, two Westphal-variant) with predominant movement disorder were randomly assigned to either the sequence of 6-week internal- or 6-week external-pallidal stimulation, or vice versa, followed by further 3 months chronic pallidal stimulation at the target with best effect-side-effect ratio. Primary endpoints were changes in the Unified Huntington’s Disease Rating Scale motor-score, chorea subscore, and total motor-score 4 (blinded-video ratings), comparing internal- versus external-pallidal stimulation, and 6 months versus baseline. Secondary endpoints assessed scores on dystonia, hypokinesia, cognition, mood, functionality/disability, and quality-of-life. RESULTS: Intention-to-treat analysis of all patients (n = 3 in each treatment sequence): Both targets were equal in terms of efficacy. Chorea subscores decreased significantly over 6 months (−5.3 (60.2%), p = 0.037). Effects on dystonia were not significant over the group due to it consisting of three responders (>50% improvement) and three non-responders. Westphal patients did not improve. Cognition was stable. Mood and some functionality/disability and quality-of-life scores improved significantly. Eight adverse events and two additional serious adverse events – mostly internal-pallidal stimulation-related – resolved without sequalae. No procedure-related complications occurred. CONCLUSION: Pallidal deep brain stimulation was demonstrated to be a safe treatment option for the reduction of chorea in Huntington’s disease. Their effects on chorea and dystonia and on quality-of-life should be examined in larger controlled trials. |
format | Online Article Text |
id | pubmed-4539552 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-45395522015-09-07 A Prospective Pilot Trial for Pallidal Deep Brain Stimulation in Huntington’s Disease Wojtecki, Lars Groiss, Stefan J. Ferrea, Stefano Elben, Saskia Hartmann, Christian J. Dunnett, Stephen B. Rosser, Anne Saft, Carsten Südmeyer, Martin Ohmann, Christian Schnitzler, Alfons Vesper, Jan Front Neurol Neuroscience BACKGROUND: Movement disorders in Huntington’s disease are often medically refractive. The aim of the trial was assessment of procedure safety of deep brain stimulation, equality of internal- and external-pallidal stimulation and efficacy followed-up for 6 months in a prospective pilot trial. METHODS: In a controlled double-blind phase six patients (four chorea-dominant, two Westphal-variant) with predominant movement disorder were randomly assigned to either the sequence of 6-week internal- or 6-week external-pallidal stimulation, or vice versa, followed by further 3 months chronic pallidal stimulation at the target with best effect-side-effect ratio. Primary endpoints were changes in the Unified Huntington’s Disease Rating Scale motor-score, chorea subscore, and total motor-score 4 (blinded-video ratings), comparing internal- versus external-pallidal stimulation, and 6 months versus baseline. Secondary endpoints assessed scores on dystonia, hypokinesia, cognition, mood, functionality/disability, and quality-of-life. RESULTS: Intention-to-treat analysis of all patients (n = 3 in each treatment sequence): Both targets were equal in terms of efficacy. Chorea subscores decreased significantly over 6 months (−5.3 (60.2%), p = 0.037). Effects on dystonia were not significant over the group due to it consisting of three responders (>50% improvement) and three non-responders. Westphal patients did not improve. Cognition was stable. Mood and some functionality/disability and quality-of-life scores improved significantly. Eight adverse events and two additional serious adverse events – mostly internal-pallidal stimulation-related – resolved without sequalae. No procedure-related complications occurred. CONCLUSION: Pallidal deep brain stimulation was demonstrated to be a safe treatment option for the reduction of chorea in Huntington’s disease. Their effects on chorea and dystonia and on quality-of-life should be examined in larger controlled trials. Frontiers Media S.A. 2015-08-18 /pmc/articles/PMC4539552/ /pubmed/26347707 http://dx.doi.org/10.3389/fneur.2015.00177 Text en Copyright © 2015 Wojtecki, Groiss, Ferrea, Elben, Hartmann, Dunnett, Rosser, Saft, Südmeyer, Ohmann, Schnitzler, Vesper and the Surgical Approaches Working Group of the European Huntington’s Disease Network (EHDN). http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Neuroscience Wojtecki, Lars Groiss, Stefan J. Ferrea, Stefano Elben, Saskia Hartmann, Christian J. Dunnett, Stephen B. Rosser, Anne Saft, Carsten Südmeyer, Martin Ohmann, Christian Schnitzler, Alfons Vesper, Jan A Prospective Pilot Trial for Pallidal Deep Brain Stimulation in Huntington’s Disease |
title | A Prospective Pilot Trial for Pallidal Deep Brain Stimulation in Huntington’s Disease |
title_full | A Prospective Pilot Trial for Pallidal Deep Brain Stimulation in Huntington’s Disease |
title_fullStr | A Prospective Pilot Trial for Pallidal Deep Brain Stimulation in Huntington’s Disease |
title_full_unstemmed | A Prospective Pilot Trial for Pallidal Deep Brain Stimulation in Huntington’s Disease |
title_short | A Prospective Pilot Trial for Pallidal Deep Brain Stimulation in Huntington’s Disease |
title_sort | prospective pilot trial for pallidal deep brain stimulation in huntington’s disease |
topic | Neuroscience |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4539552/ https://www.ncbi.nlm.nih.gov/pubmed/26347707 http://dx.doi.org/10.3389/fneur.2015.00177 |
work_keys_str_mv | AT wojteckilars aprospectivepilottrialforpallidaldeepbrainstimulationinhuntingtonsdisease AT groissstefanj aprospectivepilottrialforpallidaldeepbrainstimulationinhuntingtonsdisease AT ferreastefano aprospectivepilottrialforpallidaldeepbrainstimulationinhuntingtonsdisease AT elbensaskia aprospectivepilottrialforpallidaldeepbrainstimulationinhuntingtonsdisease AT hartmannchristianj aprospectivepilottrialforpallidaldeepbrainstimulationinhuntingtonsdisease AT dunnettstephenb aprospectivepilottrialforpallidaldeepbrainstimulationinhuntingtonsdisease AT rosseranne aprospectivepilottrialforpallidaldeepbrainstimulationinhuntingtonsdisease AT saftcarsten aprospectivepilottrialforpallidaldeepbrainstimulationinhuntingtonsdisease AT sudmeyermartin aprospectivepilottrialforpallidaldeepbrainstimulationinhuntingtonsdisease AT ohmannchristian aprospectivepilottrialforpallidaldeepbrainstimulationinhuntingtonsdisease AT schnitzleralfons aprospectivepilottrialforpallidaldeepbrainstimulationinhuntingtonsdisease AT vesperjan aprospectivepilottrialforpallidaldeepbrainstimulationinhuntingtonsdisease AT aprospectivepilottrialforpallidaldeepbrainstimulationinhuntingtonsdisease AT wojteckilars prospectivepilottrialforpallidaldeepbrainstimulationinhuntingtonsdisease AT groissstefanj prospectivepilottrialforpallidaldeepbrainstimulationinhuntingtonsdisease AT ferreastefano prospectivepilottrialforpallidaldeepbrainstimulationinhuntingtonsdisease AT elbensaskia prospectivepilottrialforpallidaldeepbrainstimulationinhuntingtonsdisease AT hartmannchristianj prospectivepilottrialforpallidaldeepbrainstimulationinhuntingtonsdisease AT dunnettstephenb prospectivepilottrialforpallidaldeepbrainstimulationinhuntingtonsdisease AT rosseranne prospectivepilottrialforpallidaldeepbrainstimulationinhuntingtonsdisease AT saftcarsten prospectivepilottrialforpallidaldeepbrainstimulationinhuntingtonsdisease AT sudmeyermartin prospectivepilottrialforpallidaldeepbrainstimulationinhuntingtonsdisease AT ohmannchristian prospectivepilottrialforpallidaldeepbrainstimulationinhuntingtonsdisease AT schnitzleralfons prospectivepilottrialforpallidaldeepbrainstimulationinhuntingtonsdisease AT vesperjan prospectivepilottrialforpallidaldeepbrainstimulationinhuntingtonsdisease AT prospectivepilottrialforpallidaldeepbrainstimulationinhuntingtonsdisease |